Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Two clinical trials show promising results in treatment for endometrial cancer, the only gynecologic cancer with rising death rates.
Both Jemperli and Keytruda improved progression-free survival in late-stage clinical trials.
Immunotherapy and … nothing else? Studies test a potential paradigm shift in treatment for some people with early stage cancers.
In a small trial, Jemperli led to complete remission in people with a biomarker for deficient DNA repair.
The immunotherapy is now approved to treat tumors with a specific genetic mutation anywhere in the body.
New checkpoint inhibitor Jemperli is approved for cancers with deficient mismatch repair mechanism for fixing damaged DNA.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.